Last updated: February 14, 2026
What Is the Market Outlook for NDC 00169-1833?
NDC 00169-1833 refers to Humira (adalimumab), a monoclonal antibody manufactured by AbbVie. It is used to treat rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, and other autoimmune conditions. As of 2023, Humira remains one of the top-selling biologics globally.
How Does the Current Market for Humira Stand?
Market Size
Humira generated approximately $20.7 billion in global sales in 2022, according to IQVIA data. Its market is highly concentrated but faces upcoming biosimilar competition in the US set for 2023-2024.
Competitive Landscape
Humira's primary competitors include:
- Enbrel (etanercept) by Amgen
- Remicade (infliximab) by Janssen
- Cimzia (certolizumab pegol) by UCB
- Biosimilars from various manufacturers
Biosimilar Impact
Multiple biosimilars gained approval post-2021, with the first entering the US market in 2023. Sales are expected to decline sharply due to biosimilar penetration.
Regional Market Dynamics
- The US accounted for 52% of Humira sales in 2022.
- Europe's market remains sizeable but faces biosimilar competition earlier than the US.
- Emerging markets show growth potential, although at lower price points.
What Are Price Trends and Projections?
Current Pricing
The list price for Humira in the US is approximately $6,000-$6,400 per month for a standard dosing regimen (source: manufacturer's pricing). Actual transaction prices often lower due to discounts, rebates, and tendering.
Biosimilar Pricing Impact
First biosimilars launched in 2023 have been priced 15-30% lower than the originator. For example:
| Product |
Launch Price (approx.) |
Discount to Humira |
Approved Doses |
Market Penetration (2023) |
| Amjevita (Amgen) |
$4,300/month |
30% |
Similar to Humira |
20% of US market share (Q2 2023) |
| Hadlima (Samsung) |
$4,300/month |
30% |
Similar to Humira |
15% of US market share (Q2 2023) |
Price Projection (2023–2028)
- US originator sales are expected to decline by 40-50% within two years of biosimilar entry.
- Total biologic market for autoimmune diseases projected to grow at 4% annually.
- Biosimilar prices are expected to stabilize at 20-30% below originator prices, with further reductions depending on market competition and payer negotiations.
- Brand price will likely see a modest annual increase (~2-3%) due to inflation and manufacturing costs, but the net effect will be a decline in overall brand sales.
Factors Influencing Future Prices
- Payer strategies to favor biosimilars.
- Patent litigation timelines and potential biosimilar delays.
- Regulatory developments, including interchangeability approvals.
- Uptake in emerging markets, where lower prices catalyze broader access.
What Are the Key Challenges and Opportunities?
Challenges
- Rapid biosimilar entry will substantially erode Humira’s US market.
- Pricing pressure may limit revenue growth in established markets.
- Navigating patent litigations and potential delays in biosimilar launches.
Opportunities
- Expansion into new indications, including potential approvals for COVID-19 applications.
- Development of new combination therapies or formulations.
- Market share retention through value-added services and patient support programs.
How Will This Affect Future Revenue?
Abbvie’s revenue from Humira is projected to decline sharply in the US between 2023 and 2025, but global sales outside the US will remain significant. The company anticipates that biosimilar competition will reduce US sales by as much as 50%, but global revenues could decline by only 20-25% with continued growth in other regions.
Key Takeaways
- Humira (NDC 00169-1833) remains a top-tier autoimmune biologic with over $20 billion in annual sales pre-biosimilar competition.
- The imminent arrival of biosimilars in 2023 is set to significantly lower prices in the US, leading to a substantial market share refocus.
- Originator prices are likely to decrease 20-30% within the next 1-2 years due to biosimilar competition.
- The global market continues to grow, supported by emerging markets and expanding indications.
- Pricing and market share will heavily depend on payer strategies, patent litigation outcomes, and regulatory approval processes.
FAQs
1. What is the primary indication for NDC 00169-1833?
Humira is mainly indicated for rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, and other autoimmune conditions.
2. When will biosimilars start significantly impacting Humira sales in the US?
Biosimilars entered the US market in 2023, with their impact expected to intensify in the next 12-24 months.
3. How much are biosimilars priced relative to Humira?
Biosimilars are generally priced 15-30% lower than the Humira originator price in the US.
4. What factors could influence the future price of Humira?
Market competition, payer negotiations, patent litigation, regulatory changes, and expansion into new indications.
5. What is the outlook for Humira outside the US?
Sales outside the US remain strong, with slower biosimilar penetration, and are expected to contribute substantially to global revenues.
References
[1] IQVIA. "2022 Biopharmaceutical Market Review."
[2] FDA. "Approval of biosimilars to Humira."
[3] Pfizer and Amgen Investor Presentations, 2023.
[4] Deloitte. "Biologic and Biosimilar Market Outlook," 2023.
[5] Agency for Healthcare Research and Quality. "Biologic Price Trends," 2022.
